NCI Cancer News

Syndicate content National Cancer Institute
The latest cancer news from the U.S. government's principal agency for cancer research.
Updated: 18 min 50 sec ago

NCI launches study of African-American cancer survivors

Mon, 02/27/2017 - 00:00

The Detroit Research on Cancer Survivors (ROCS) study, which will include 5,560 cancer survivors, will look at the major factors affecting cancer progression, recurrence, mortality, and quality of life among African-American cancer survivors.

Categories: NCI News

Study finds premature death rates diverge in the United States by race and ethnicity

Wed, 01/25/2017 - 00:00

Premature death rates declined among Hispanics, blacks, and Asian/Pacific Islanders due mainly to fewer deaths from cancer, heart disease, and HIV. Rising deaths from accidents, drug overdoses, suicide and liver disease increased rates among whites and American Indian/Alaska Natives.

Categories: NCI News

TCGA study identifies genomic features of cervical cancer

Mon, 01/23/2017 - 00:00

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in subclassification of the disease and may help target therapies that are most appropriate for each patient.

Categories: NCI News

New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials

Wed, 01/11/2017 - 00:00

The National Cancer Institute (NCI) today launched a new drug formulary (the “NCI Formulary”) that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials. The NCI Formulary could ultimately translate into speeding the availability of more-effective treatment options to patients with cancer.

Categories: NCI News

Early-phase trial demonstrates shrinkage in pediatric neural tumors

Wed, 12/28/2016 - 00:00

In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage.

Categories: NCI News

Early-phase trial demonstrates shrinkage in pediatric neural tumors

Wed, 12/28/2016 - 00:00
In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage.
Categories: NCI News

Cellular Immunotherapy Targets a Common Human Cancer Mutation

Wed, 12/07/2016 - 00:00

In a study of an immune therapy for colorectal cancer that involved a single patient, researchers identified a method for targeting the cancer-causing protein produced by a mutant form of the KRAS gene.

Categories: NCI News

Cellular Immunotherapy Targets a Common Human Cancer Mutation

Wed, 12/07/2016 - 00:00
In a study of an immune therapy for colorectal cancer that involved a single patient, researchers identified a method for targeting the cancer-causing protein produced by a mutant form of the KRAS gene.
Categories: NCI News